FrieslandCampina, NIZO, NutriLeads Join Forces to Accelerate Health Benefits Development

5ac60db6-3d4a-417c-a596-48eb5564b11barticleimage.jpg

08 Jun 2017 --- FrieslandCampina, NIZO and NutriLeads are joining forces in the Challenge consortium, which will aim to develop new food ingredients that will support resistance to infections, as well as affordable and predictive research models in healthy volunteers to allow companies accelerated market access.

“Infections of the upper airways and the gut are an important cause of morbidity and mortality worldwide. Medicines are not always the solution and can be expensive. Therefore, it would be of interest to study if components in food can help to increase the immune defense of humans against infections as preventive measure,” Marjolijn Bragt, Manager Nutritional Sciences at FrieslandCampina, tells NutritionInsight

The results will benefit infants, young children and elderly in particular, but healthy adults could also benefit from the research, Bragt says.

“FrieslandCampina wants to contribute towards feeding the world population and focuses on improving its products to contribute to the consumer needs. The innovative power of Challenge is expressed in the evaluation of translational biomarkers for infants and children,” she adds. 

A spokesperson for NIZO noted how the company has developed human challenge models for determining how the human body can cope with such “challenges” to infection resistance. In these models, researchers apply moderate stresses, such as a vaccination or a gut or respiratory infection. These challenge studies include a control group and a group that receives potentially resistance boosting ingredients who are afterwards both exposed to an attenuated (i.e. debilitated) gut or respiratory pathogen.

“The aim of the consortium is to develop methods to be able to show and substantiate potential immune modulating effects of food and food components. To this end, in vitro immune assays and in vivo Challenge studies are included. In the Challenge studies, healthy human volunteers will be exposed to weakened bacteria, viruses or vaccines. It will be tested if food or food components can improve the immune response of the body upon this challenge,” Bragt notes.

Click to EnlargeWithin the Challenge project NutriLeads will "perform a human trial to test the effect of its lead ingredient on resistance to common respiratory infections. The design of the trial will be based on a challenge model, more specifically a proven common cold infection model, in which trial volunteers will be challenged with a common cold virus to assess the protective effect of our food ingredient against this model infection,” Ruud Albers, CEO of NutriLeads, tells NutritionInsight.

Albers adds that the company “strongly believes in the Human Challenge Model concept" and that "the Challenge consortium is a logical next step in substantiating the immune supportive effect of our lead ingredient, a novel Immune Modulating Plant Polysaccharide.”

In terms of the active ingredients the consortium will be looking into, Bragt underlines that as a dairy cooperative with scientific expertise on the nourishing aspects of milk and its dairy chain, FrieslandCampina will focus on “dairy components that have the potential to improve the immune response.”

Speaking on the challenges current regulation poses in terms of the body of science required to prove the efficacy of active compounds, Albers notes that “within the current regulatory framework, it is important to demonstrate clinically relevant effects, biological plausibility and cause-effect relationships. Challenge models such as the common cold infection model that NutriLeads will use can help to do so within a controlled setting in a relevant human target population.”

Bragt adds: “To be able to make claims, thorough substantiation is needed and also requested by regulation. You have to build a scientific dossier with studies of the right quality and quantity, using the right methods, endpoints and biomarkers. This consortium enables us to build substantial evidence on the potential of dairy components to improve the immune response.”

According to Bragt, the Challenge model can be an important step to fill the gap between in vitro laboratory studies and large scale and expensive field studies in humans. This will eliminate the need for animal testing, a testing method Royal FrieslandCampina refrains from using. 

According to Alwine Kardinaal, project leader at NIZO, “The combined research power of the companies involved is unique and will enable [the companies] to take the next step in predicting health benefits with the use of Human Challenge Studies. Especially in nutrition research, challenge studies are a unique approach to induce a physiological response in healthy subjects and to investigate how an active ingredient modulates this response. Given NIZO’s reputation with i.e. the ETEC model, we are confident to lead this exciting project.”

Both Bragt and Albers note that the companies will be testing their own products, but will be working closely together to assess the effects of different food components.

“We definitely aim for synergy in this consortium, by bundling knowledge and expertise to develop innovative methods to demonstrate the immune modulating properties of food components. In one of these models, we will test our own product. Based on the shared learnings from the partners, we can determine the predictive value of in vitro laboratory studies and in vivo Challenge studies to establish immune modulating effects of food components,” Bragt says.

“Within the project, NutriLeads will test its own functional ingredient, and together with NIZO and Friesland Campina, we will further develop and validate challenge models in humans to assess health effects of food ingredients and food products,” Albers concludes.

According to a press release issued by NIZO, the Challenge project has a total budget of €3.7 million (US$4.2 million), of which €1.5 million will be co-financed by the EU and EFRO OP-Oost. The subsidy was granted in Q2 2017; first results will become available later this year.

by Lucy Gunn

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Nutrition & Health News

Microbiome solutions: A key theme at Vitafoods Europe 2018

24 May 2018 --- Research into the microbiome – the aggregated microbial species in our body – is gaining increasing attention and investment. Although the term is often associated with digestive health, the body, in fact, contains multiple microbiome. This is currently spurring on research and innovation in areas as wide-ranging as women’s health, weight management, immunity and skin health. At Vitafoods Europe 2018, NutritionInsight spoke with suppliers about their efforts and innovations in the microbiome space, using pre or probiotics for gut health and beyond.

Nutrition & Health News

Athletic endurance improved with Beneo's low glycemic carb, study finds

24 May 2018 --- Athletes who consumed a drink containing the functional carbohydrate, Palatinose, before exercise exhibited improved cycling performance, a study at the University of Freiburg has found. This was in comparison with participants who were given maltodextrin, a high glycemic carbohydrate, before exercising. The study's findings could hold potential for the use of Palatinose as a sports nutrition ingredient.

Nutrition & Health News

Nutrient breakthrough: Scientists show plants can be a dietary source of vitamin B12

24 May 2018 --- Scientists at the University of Kent have made a significant discovery about how the vitamin B12 content of some plants can be improved to make vegetarian and vegan diets more complete. Vitamin B12 (known as cobalamin) is an essential dietary component but vegans and vegetarians are more prone to B12 deficiency as plants neither make nor require this nutrient.

Nutrition & Health News

US FDA takes action against OTC benzocaine products for teething infants

24 May 2018 --- The US Food and Drug Administration (FDA) has warned that over-the-counter (OTC) teething products containing benzocaine may pose a serious risk to infants and children. The popular numbing agent can offer temporary relief to sore gums in teething infants; however, the FDA advises that companies stop marketing and selling these products for use. The agency is also raising awareness of the risks that, they state, come with other oral health benzocaine products. 

Nutrition & Health News

UK sugar reduction efforts fail to reach initial target, industry urged to step up or face tax

23 May 2018 --- The first assessment of the UK government’s sugar reduction program has unveiled failings by industry to reduce sugar in the first year by 5 percent, leading to calls of a sugar tax on sweet treats. The results of the first year have been roundly criticized in the media and described as “hugely disappointing” after Public Health England data revealed that sugar was cut in some categories – sweet spreads and sauces, yogurts and fromage frais and breakfast cereals – while other food groups have fallen short.

More Articles
URL : http://www.nutritioninsight.com:80/news/frieslandcampina-nizo-nutrileads-join-forces-to-accelerate-health-benefits-development.html